他氟前列素：全球首次批准。
Tavaborole: first global approval.
机构信息
Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand,
出版信息
Drugs. 2014 Sep;74(13):1555-8. doi: 10.1007/s40265-014-0276-7.
PMID:25118637
Abstract
Tavaborole is a novel, low-molecular weight oxaborole antifungal drug under development by Anacor Pharmaceuticals Inc. for the topical treatment of onychomycosis of the toenail. The drug has received its first global approval for this indication in the US. This article summarizes the milestones in the development of tavaborole leading to this first approval for onychomycosis of the toenails.
摘要
他氟前列素是一种新型的、低分子量的氧杂硼烷类抗真菌药物，由 Anacor Pharmaceuticals Inc. 开发，用于局部治疗脚趾甲的甲真菌病。该药物已在美国获得该适应症的全球首次批准。本文总结了他氟前列素开发过程中的重要里程碑，最终获得了用于治疗脚趾甲甲真菌病的首次批准。
Zotero 插件